http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
PureTech Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate LYT-200 and Tislelizumab in Patients with Difficult-to-Treat Solid Tumors
-
PureTech Founded Entity Vedanta Biosciences Announces New Data from Phase 1 Study of VE202 for the Treatment of Inflammatory Bowel Disease
-
PureTech Founded Entity Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers
-
PureTech Health Plc (PRTC) Acquires Remaining Interest in Founded Entity Alivio Therapeutics
-
PureTech Acquires Remaining Interest in Founded Entity Alivio Therapeutics
-
Results of Annual General Meeting
-
PureTech Founded Entity Gelesis Presents Findings on Plenity®-Induced Weight Loss at the American Association of Clinical Endocrinology (AACE) 2021 Annual Virtual Meeting
-
PureTech (PRTC) Founded Entity Akili Secures $160 Million in Financing
-
PureTech Founded Entity Akili Secures $160 Million in Financing; Poised to Deliver on the Promise of Digital Therapeutics
-
PureTech to Present at the Jefferies Virtual Healthcare Conference
-
PureTech Forms Clinical Advisory Board for Idiopathic Pulmonary Fibrosis and Related Lung Disorders
-
PureTech Announces Nature Publication Supporting Modulation of Meningeal Lymphatics to Target Alzheimer’s Disease Pathologies
-
PureTech Health Plc (PRTC) Adds Jane Wildman to Board
-
PureTech Founded Entity Gelesis Appoints Procter & Gamble Veteran Jane Wildman to Board of Directors
-
PureTech Announces Annual Results for Year Ended December 31, 2020
-
PureTech Health Plc (PRTC)
-
PureTech Presents Promising Preclinical Data from LYT-210 Immuno-Oncology Program at American Association for Cancer Research (AACR) Annual Meeting
-
PureTech to Present at Two Upcoming Investor Conferences
-
PureTech Founded Entity Akili Collaborates with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to Study Digital Therapeutic AKL-T01 as Potential Treatme
-
PureTech (PRTC) Founded Entity Akili Announces Results of EndeavorRx Clinical Study in Pediatric ADHD Published in Nature Digital Medicine
-
PureTech Founded Entity Akili Announces the Results of EndeavorRx™ Clinical Study in Pediatric ADHD Published in Nature Digital Medicine
-
PureTech Announces Board Member Retirement
-
PureTech: Notice of Results
-
PureTech to Present at The Barclays Global Healthcare Conference
-
PureTech Announces Publication of Glyph™ Platform Preclinical Proof-of-Concept Study in Journal of Controlled Release
-
PureTech Founded Entity Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in Schizophrenia
-
PureTech to Present at The SVB Leerink 10th Annual Global Healthcare Conference
-
PureTech Health (PRTC) Receives Approximately $118 Million from Sale of Portion of Founded Entity Shares
-
PureTech Founded Entity Vor Biopharma Closes Over $200M Initial Public Offering
-
PureTech Receives Approximately $118 Million from Sale of Portion of Founded Entity Shares
-
PureTech Founded Entity Vedanta Biosciences Appoints Mark Mullikin as Chief Financial Officer
-
PureTech Founded Entity Vor Biopharma Announces Pricing of Initial Public Offering
-
PureTech Adds Bharatt Chowrira, PureTech’s President and Chief of Business and Strategy, to Board of Directors
-
PureTech Health Plc (PRTC) Founded Entity, Vor Biopharma, Announces FDA Clearance of IND Application for VOR33
-
PureTech Founded Entity Vor Announces FDA Clearance of IND Application for VOR33
-
PureTech Founded Entity Follica Adds Two Leaders in Aesthetic Medicine and Dermatology to its Board of Directors
-
PureTech (PRTC) Founded Entity Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.
-
PureTech Founded Entity Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.
-
PureTech Health Plc (PRTC) Names George Farmer CFO
-
PureTech Announces the Appointment of George Farmer, Ph.D., as Chief Financial Officer
-
PureTech to Present at 38th Annual J.P. Morgan Healthcare Conference and Other Conferences
-
PureTech Advances Wholly Owned Candidate LYT-200 into Phase 1 Trial for Potential Treatment of Metastatic Solid Tumors
-
PureTech Health Plc (PRTC) Begins Phase 2a trial of LYT-100 (Deupirfenidone) in Lymphedema
-
PureTech Initiates Phase 2a trial of LYT-100 (Deupirfenidone) in Lymphedema
-
PureTech Founded Entity Follica Announces Pilot Study for Female Pattern Hair Loss Published in International Journal of Women’s Dermatology
-
PureTech Initiates Phase 2 trial of LYT-100 (Deupirfenidone) in Long COVID Respiratory Complications and Related Sequelae
-
PureTech to Host Virtual R&D Day for Investors on December 11, 2020
-
PureTech Founded Entity Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors
-
PureTech Health Plc (PRTC) Reports LYT-100 (Deupirfenidone) Demonstrates Tolerability and Pharmacokinetic Proof-of-Concept in Phase 1 Multiple Ascending Dose & Food Effect Study
-
PureTech’s LYT-100 (Deupirfenidone) Demonstrates Tolerability and Pharmacokinetic Proof-of-Concept in Phase 1 Multiple Ascending Dose and Food Effect Study

